Avidity Biosciences Inc
RNAM
Classificação em ações
#2082
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Preço da ação
$71.34
Última sincronização: 2026-03-03
Valor de mercado
$9.84B
Variação (1 dia)
0.00%
Variação (1 ano)
-
País
US
Negociar Avidity Biosciences Inc (RNAM)
Categoria
Healthcare
Histórico de rendimento de dividendos para Avidity Biosciences Inc (RNAM)
O rendimento de dividendos (TTM) da Avidity Biosciences Inc (símbolo da ação: RNAM) em 2026 é: 0
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Histórico de rendimento de dividendos para Avidity Biosciences Inc (RNAM) de 2018 a 2026
Rendimento de dividendos no final de cada ano (TTM)
| Ano | Rendimento de Dividendos | Alterar |
|---|---|---|
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Rendimentos de dividendos (TTM) para empresas semelhantes ou concorrentes
| Empresa | Rendimento de Dividendos | País |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.07% |
AU
|
|
| 0.00% |
NL
|
|
| 0.72% |
BE
|
